Godavari Drugs (BOM:530317) Research & Development: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530317 Godavari Drugs Ltd BOM:530317
54 GF Score
Price ₹102.50
GF Value ₹72.35
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Godavari Drugs Research & Development?

Godavari Drugs BOM:530317 -0.49% 54 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:530317 with a GF Score™ of 54/100 and a GF Value™ of ₹72.35 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Godavari Drugs's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Godavari Drugs  (BOM:530317) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Godavari Drugs Research & Development Related Terms

Godavari Drugs Research & Development Historical Data

* Premium members only.

The historical data trend for Godavari Drugs's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Godavari Drugs Research & Development Chart

Godavari Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.88 2.82 3.25 2.34 0.00

Godavari Drugs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:530317
54GF Score
Godavari Drugs Ltd BOM:530317
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Godavari Drugs Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Godavari Drugs (BOM:530317) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Godavari Drugs and its competitors.
Is Godavari Drugs' Research & Development too high?
Godavari Drugs' current Research & Development is ₹0 Mil. Overall, Godavari Drugs has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Godavari Drugs' Research & Development compare to ZTS?
Godavari Drugs' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Godavari Drugs and its competitors. Godavari Drugs's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Godavari Drugs stock overvalued right now?
Based on GuruFocus' analysis, Godavari Drugs (BOM:530317) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹72.35, compared to a current price of ₹102.50 — trading 41.7% above its estimated fair value. The current Research & Development is ₹0 Mil. Godavari Drugs' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Godavari Drugs (BOM:530317), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Godavari Drugs (BOM:530317) Overvalued in 2026?

Based on GuruFocus' analysis, Godavari Drugs stock appears to be overvalued. The current stock price of ₹102.50 is trading 41.7% above its estimated GF Value™ of ₹72.35. GuruFocus considers Godavari Drugs to be Significantly Overvalued.

Key valuation signals for BOM:530317:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹72.35 vs. price of ₹102.50 (41.7% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the BOM:530317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Godavari Drugs Business Description

Address Sardar Patel Road, 1-8-303/34, Mayfair, 1st Floor, Secunderabad, TG, IND, 500 003
Godavari Drugs Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing of APl's, intermediates and fine chemicals,. The firm's product includes Ciprofloxacin hydrochloride, ciprofloxacin, ciprofloxacin lactate, ciprofloxacin lactate, and Others. The company operates only one segment which is the manufacture and sale of Active Pharmaceutical Ingredients (API) and its intermediates.
54GF Score

Get the complete analysis for BOM:530317

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹102.50
Price
₹72.35
GF Value